Screener
Amgen AMGN Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales | $9,537 | $8,771 | $17,755 | $16,644 |
| Other revenues | 517 | 408 | 917 | 684 |
| Total revenues | 10,054 | 9,179 | 18,672 | 17,328 |
| Less: | ||||
| Manufacturing cost of sales(1)(2) | 2,139 | 2,484 | 4,319 | 5,012 |
| Profit share and royalties in cost of sales(1) | 672 | 527 | 1,236 | 967 |
| Research and development(1) | 1,868 | 1,744 | 3,587 | 3,230 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's business segments — total revenues?
- Amgen (AMGN) reported business segments — total revenues of $10.05B in Q2 2026.
- How has Amgen's business segments — total revenues changed year-over-year?
- Amgen's business segments — total revenues increased by 9.5% year-over-year, from $9.18B to $10.05B.
- What does business segments — total revenues mean?
- Represents the total gross revenue generated by the company's primary business segments from the sale of biotechnology therapeutics. This figure serves as the top-line indicator of market demand for the company's portfolio of drugs and biologics. It is a critical measure of the company's overall scale and commercial success in the global pharmaceutical market.
Ask your AI about Amgen's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude